Left atrial appendage occlusion using a Watchman device in a transplanted heart with biastral anastomosis

INTRODUCTION

- Biastral anastomosis orthotopic heart transplant (OHT) results in enlarged atria, scarred and thickened interatrial septum, and leftward rotation of the heart, thereby complicating left atrial appendage (LAA) closure.

- This report describes successful LAA occlusion in a patient with previous biastral anastomosis OHT using the WATCHMAN™ Device and the radiofrequency (RF) NRG™ Transseptal Needle (Baylis Medical) for controlled crossing of the septum.

METHODS AND RESULTS

Transseptal puncture

- Transesophageal echocardiography (TEE) indicated a thickened interatrial septum from the prior biastral anastomosis and scar tissue.

- Site-specific transseptal puncture in the inferio-posterior location of the fossa ovalis was achieved using the NRG™ Needle with minimal additional force.

LAA occlusion

- Standard TEE views (0°, 45°, 90°, and 135°) were adjusted by 10-20° to account for the effects of biastral anastomosis and replicate the desired LAA ostial views for appropriate device sizing.

- Successful deployment of a 21 mm WATCHMAN™ Device into the LAA was achieved with no complications.

- 45 days post-operative TEE indicated no thrombus formation or residual flow in the LAA.

- Anticoagulation was administered for 45 days, while antiplatelet therapy was continued for six months post-procedure, respectively.

DISCUSSION AND CONCLUSIONS

- Changes in atrial morphology and leftward rotation of the heart, such as those seen in this patient with biastral anastomosis OHT, can make standard WATCHMAN™ implantation difficult.

- Site-specific transseptal puncture and firm engagement of the interatrial septum can be complicated by scarring and thickening of the septum, and may result in accidental puncture and perforation.

- Additional balloon dilation of the septum may be required to advance the large LAA occluder sheath into the left atrium.

- The NRG™ Transseptal Needle was used to provide controlled site-specific crossing of the interatrial septum without complications.

- Using a radiofrequency needle can enable simpler and safer access to the left atrium, without requiring extra force application.

- LAA occlusion using the WATCHMAN™ Device in a patient with prior biastral anastomosis OHT can be safely and successfully performed using the described procedural modifications.

* A wholly-owned subsidiary of Boston Scientific Corporation.
Brief Summary | NRG™ Transseptal Needle

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

INDICATIONS FOR USE: The NRG™ Transseptal Needle is used to create an atrial septal defect in the heart. Secondary indications include monitoring intracardiac pressures, sampling blood, and infusing solutions.

CONTRAINDICATIONS: The NRG™ Transseptal Needle is not recommended for use with any conditions that do not require cutting or cauterization of soft tissue.

WARNINGS: • Placement of the dispersive electrode on the thigh or hip could be associated with higher impedance. • To prevent the risk of ignition make sure that flammable material is not present in the room during RF power delivery. • Careful needle manipulation must be performed to avoid cardiac damage or tamponade. Needle advancement should be done under image guidance. If resistance is encountered, DO NOT use excessive force to advance or withdraw the needle. • During power delivery, the patient should not be allowed to come in contact with ground metal surfaces. • Thoroughly flush the NRG™ Transseptal Needle with heparinized saline solution prior to use.

ADVERSE EVENTS: Adverse events that may occur while using the Baylis Medical Radiofrequency Puncture System include: • Tendonitis • Sepsis/Infection • Thromboembolic episodes • Vessel perforation • Atrial Fibrillation • Myocardial Infarction • Vessel spasm • Sustained arrhythmias • Atrial Flutter • Hemorrhage • Vascular thrombosis • Perforation of the myocardium • Hematoma • Allergic reaction to contrast medium • Venricular Tachycardia • Pain and Tenderness • Thermal damage to tissue • Arteriovenous fistula • Pericardial Effusion.

Brief Summary | WATCHMAN FLX™ Device

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

INTENDED USE / INDICATIONS FOR USE: The WATCHMAN FLX Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who: Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASC scores and are recommended for anticoagulation therapy; Are deemed by their physicians to be suitable for anticoagulation therapy; and Have an appropriate rationale to seek alternative antithrombotic therapy, taking into account the safety and effectiveness of the device compared to anticoagulation therapy.

CONTRAINDICATIONS: Do not use the WATCHMAN FLX Device if: Intercardiac thrombus is present; An atrial septal defect repair or closure device or a patient foramen ovale repair or closure device is present. The LAA anatomy will not accommodate a Closure Device (see Table 45 of the eIFU). The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section of the eIFU) such that the use of the WATCHMAN FLX Device is contraindicated. Any of the customary contraindications for other percutaneous catheterization procedure (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present. There are contraindications to the use of anticoagulation therapy, aspirin, or P2Y12 inhibitor.

WARNINGS: Impartation of the WATCHMAN FLX Device should only be performed by interventional cardiologists and/or electrophysiologists who are trained in percutaneous and transseptal procedures and who have completed the WATCHMAN FLX Physician Training Program. This device has not been studied in pregnant or breastfeeding women. Careful consideration should be given to the use of the Closure Device in pregnant and/or breastfeeding women due to the risk of significant exposure to x-rays, and the use of anticoagulation medication. Device selection should be based on accurate LAA measurements obtained using echocardiographic imaging guidance in multiple views (TEE recommended in multiple angles [e.g., 0°, 45°, 90°, 135°]) to avoid improper Closure Device sizing. Do not release (i.e., unscrew) the WATCHMAN FLX Device from the core wire unless all release criteria are satisfied to avoid suboptimal results. Potential for closure device movement should be assessed within 30 days following Closure Device implantation; verify Closure Device position after cardioversion during this period. Appropriate post-procedure drug therapy should be followed. See Post-Procedure Information section (of the eIFU) for further detail.


All trademarks are property of their respective owners. Patents Pending and/or issued. CAUTION: The law restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Instructions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions. Please contact your Boston Scientific representative for local labeling, product specifications and licensed model numbers.

© 2023 Boston Scientific Corporation or its affiliates. All rights reserved.